Aeterna Zentaris Inc.

Equities

AEZS

CA0079756007

Biotechnology & Medical Research

End-of-day quote Toronto S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
11.57 ^CAD	+0.17%		+4.33%	+12.55%

17/05	Aeterna Zentaris Finalizes Some Details for Ceapro Merger	MT
17/05	Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	MT

Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 04, 2022 at 04:40 am IST

Aeterna Zentaris Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.037 million compared to USD 0.043 million a year ago. Negative revenue was USD 0.222 million compared to revenue of USD 1.58 million a year ago. Net loss was USD 4.22 million compared to USD 2.08 million a year ago. Basic loss per share from continuing operations was USD 0.87 compared to USD 0.43 a year ago. Diluted loss per share from continuing operations was USD 0.87 compared to USD 0.43 a year ago.
For the six months, sales was USD 0.08 million compared to USD 0.084 million a year ago. Revenue was USD 1.3 million compared to USD 3.25 million a year ago. Net loss was USD 6.86 million compared to USD 3.54 million a year ago. Basic loss per share from continuing operations was USD 1.41 compared to USD 0.82 a year ago. Diluted loss per share from continuing operations was USD 1.41 compared to USD 0.82 a year ago.

Latest news about Aeterna Zentaris Inc.

Aeterna Zentaris Finalizes Some Details for Ceapro Merger	17/05	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	17/05	MT
MT Newswires Canada Overnight Stocks To Watch: Aeterna Zentaris; Orla Mining; Andlauer Healthcare; CES Energy Solutions; Imperial Metals; Sulliden	15/05	MT
Aeterna Zentaris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
North American Morning Briefing : Stocks Edge -2-	27/03	DJ
North American Morning Briefing : Markets on Hold -2-	20/03	DJ
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	26/02	MT
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell	18/12	MT
Top Premarket Gainers	18/12	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14/12	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	14/12	MT
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction.	29/11	CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs	16/11	DJ
HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating	13/11	MT
Aeterna Zentaris Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
North American Morning Briefing : Traders Await -2-	09/11	DJ
North American Morning Briefing : China Angst -2-	15/23/15	DJ
Aeterna Zentaris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI

Chart Aeterna Zentaris Inc.

Duration

Period

More charts

Company Profile

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Sector

Biotechnology & Medical Research

Calendar

02/07/2024 - Annual General Meeting

More about the company

	1st Jan change	Capi.
AETERNA ZENTARIS INC.	+12.55%	10.32M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research